UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Liver international, 2019-08, Vol.39 (8), p.1468-1477

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Investigational new drugs, 2020-10, Vol.38 (5), p.1570-1579

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Drug design, development and therapy, 2015-01, Vol.9 (default), p.4479-4499

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

BMC cancer, 2023-07, Vol.23 (1), p.708-708, Article 708

2023

Link zum Volltext

Verfügbarkeit prüfen

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2023-04, Vol.9 (2), p.e12404-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs

Journal of pharmacokinetics and pharmacodynamics, 2007-06, Vol.34 (3), p.313-331

2007

Link zum Volltext

Verfügbarkeit prüfen

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1258-1267

2023

Link zum Volltext

Verfügbarkeit prüfen

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Alzheimer's & dementia, 2023-06, Vol.19 (S7), p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

Clinical cancer research, 2019-12, Vol.25 (23), p.6976-6985

2019

Link zum Volltext

Verfügbarkeit prüfen

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

European journal of pharmaceutical sciences, 2021-06, Vol.161, p.105781-105781, Article 105781

2021

Link zum Volltext

Verfügbarkeit prüfen

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Alzheimer's & dementia, 2023-06, Vol.19 (6), p.2253-2264

2023

Link zum Volltext

Verfügbarkeit prüfen

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

European journal of cancer (1990), 2016-10, Vol.66, p.95-103

2016

Link zum Volltext

Verfügbarkeit prüfen

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Pharmaceutical research, 2014-10, Vol.31 (10), p.2829-2843

2014

Link zum Volltext

Verfügbarkeit prüfen

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Alzheimer's & dementia, 2023-12, Vol.19 (S14), p.n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.717-727

2016

Link zum Volltext

Verfügbarkeit prüfen

ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA

Neuro-oncology (Charlottesville, Va.), 2016-11, Vol.18 (suppl_6), p.vi4-vi4

2016

Link zum Volltext

Verfügbarkeit prüfen

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Journal of pharmacokinetics and pharmacodynamics, 2004-06, Vol.31 (3), p.185-213

2004

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

Journal of thoracic oncology, 2021-02, Vol.16 (2), p.327-333

2021

Link zum Volltext

Verfügbarkeit prüfen

Mechanism for Enhanced Absorption of a Solid Dispersion Formulation of LY2300559 Using the Artificial Stomach Duodenum Model

Molecular pharmaceutics, 2015-04, Vol.12 (4), p.1131-1140

2015

Link zum Volltext

Verfügbarkeit prüfen

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Xenobiotica, 2018-04, Vol.48 (4), p.382-399

2018

Link zum Volltext

Verfügbarkeit prüfen

Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data

Drug metabolism and disposition, 2002-03, Vol.30 (3), p.276

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2046: Exposure - response (overall survival [OS]) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in a randomized phase 2, double-blind study

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2046-2046

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2046: Exposure - response (overall survival OS) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertibgemcitabine (GG) or gemcitabineplacebo (GP) in a randomized phase 2, double-blind study

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2046-2046

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of galunisertib (TGF-Β R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.4097-4097

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 61

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(60)
Dissertationen
(1)

Sprache

Englisch
(61)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer

ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

Mechanism for Enhanced Absorption of a Solid Dispersion Formulation of LY2300559 Using the Artificial Stomach Duodenum Model

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Abstract 2046: Exposure - response (overall survival [OS]) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in a randomized phase 2, double-blind study

Abstract 2046: Exposure - response (overall survival OS) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertibgemcitabine (GG) or gemcitabineplacebo (GP) in a randomized phase 2, double-blind study

A phase 2 study of galunisertib (TGF-Β R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Aktive Filter

Suchergebnisse filtern